葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

交易中 06-29 12:37:02 EDT

52.48

-0.02

-0.04%

最高52.56	最低52.11	成交量240.63万
今开52.46	昨收52.50	日振幅0.86%
总市值1,062亿	流通市值1,022亿	总股本20.24亿
成交额1.26亿	换手率0.12%	流通股本19.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":52.475,"timestamp":1782751021569,"preClose":52.495,"halted":0,"volume":2406297,"delay":0,"changeRate":-0.000380988665587123,"floatShares":1946891708,"shares":2023763538,"eps":3.736205,"marketStatus":"交易中","change":-0.02,"latestTime":"06-29 12:37:02 EDT","open":52.46,"high":52.555,"low":52.105,"amount":125959228.68399,"amplitude":0.008572,"askPrice":52.47,"askSize":144,"bidPrice":52.46,"bidSize":126,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1782763200000},"marketStatusCode":2,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":52.495,"dividendRate":0.033807,"preHourTrading":{"tag":"盘前","latestPrice":52.46,"preClose":52.495,"latestTime":"09:29 EDT","volume":72279,"amount":3786119.6621850003,"timestamp":1782739799208,"change":-0.035,"changeRate":-0.000667,"amplitude":0.006601},"postHourTrading":{"tag":"盘后","latestPrice":52.69,"preClose":52.5,"latestTime":"19:29 EDT","volume":781,"amount":41015.2987,"timestamp":1782516578864,"change":0.19,"changeRate":0.003619,"amplitude":0.003619},"volumeRatio":1.371833,"optionData":{"bulkOrders":[{"symbol":"GSK","call":false,"expireDate":1787284800000,"strike":"45.0","timestamp":1782750197967,"price":0.45,"volume":14000,"amount":630000,"type":"+"},{"symbol":"GSK","call":false,"expireDate":1787284800000,"strike":"50.0","timestamp":1782750197967,"price":1.4,"volume":7000,"amount":980000,"type":"-"}]},"impliedVol":0.3151,"impliedVolPercentile":0.6494},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2645281618","title":"葛兰素史克宣布要约收购Nuvalent。","url":"https://stock-news.laohu8.com/highlight/detail?id=2645281618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645281618?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:54","pubTimestamp":1782309271,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4539","GSKH","BK4139","BK4532","GSK.UK","NUVL","GSK","LU1829250122.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756361","title":"摩根大通：生物药企融资回暖 大型药企行业并购优先级高于独立IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756361?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:21","pubTimestamp":1781605294,"startTime":"0","endTime":"0","summary":"多数本土生物科技企业采取双轨策略，同步筹备 IPO、对接药企收购资源，不少企业上市落地前完成并购交割。头部药企偏好数十亿美金中型补充式并购，近期葛兰素史克斥资 106 亿美元收购肿瘤药企 Nuvalent，打破中小型并购定价惯例。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0976567544.SGD","IE0009355771.USD","SG9999002224.SGD","LU2211815571.USD","IE00BYXW3230.USD","IPOS","PGF","JPX","LU2592432038.USD","GSKH","LU0251132253.USD","IE00BKDWB100.SGD","LU0211331839.USD","IE00B2B36J28.USD","LU0964807845.USD","LU0265550946.USD","LU0238689110.USD","IE00BJJMRZ35.SGD","159839","LU1261432733.SGD","BK4504","LU0640476718.USD","IE00B3S45H60.SGD","LU2357305700.SGD","LU2237443622.USD","NVS","LU1548497426.USD","LU0345769128.USD","LU1366192091.USD","LU0689472784.USD","LU0215105999.USD","LU0070302665.USD","LU0310799852.SGD","LU0942090050.USD","JPO","LU1629891620.HKD","IE0034235303.USD","LU2505996509.AUD","GSK.UK","BK4566","IE00B1XK9C88.USD","JPM","LU2357627491.SGD","LU1064131342.USD","LU1894683348.USD","GSK","JPMO","BK4578","LU1496350502.SGD","LU0820562030.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286033","title":"GSK十年来最大一笔并购，对中国Biotech的四点启示","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286033","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642286033?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:59","pubTimestamp":1781175583,"startTime":"0","endTime":"0","summary":"这事儿，挺值得咱们中国的Biotech琢磨琢磨的。过去十年，中国创新药习惯了自己的坐标系。中国Biotech肯定不缺科学，但这种跳出自身坐标系、站在买家视角重新丈量自己价值的自觉，或多或少差了些。这对咱们中国Biotech第二个启示，就是别再净那些“万金油”式的东西了。而GSK这次可不一样。这，或许就是那张价值106亿美元倒计时牌，给咱们的Biotech上的最好一课。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1781143796640652546","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4581","BK4532","GSK.UK","XBI","LU1829250122.USD","GSKH","GSK","BK4585","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642189402","title":"重返肿瘤核心战场 葛兰素史克(GSK.US)能否借Nuvalent缩小与阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642189402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4568","LU0889565916.HKD","BK4585","IE00B3T34201.USD","LU2237443895.HKD","GSK.UK","LU0320765992.SGD","AZNH","LU2237443622.USD","BK4539","AZN","LU2462157665.USD","LU2456880835.USD","BK4139","LU1829250122.USD","LU2237443382.USD","LU2237443549.SGD","LU0058720904.USD","NUVL","LU0289739699.SGD","LU2236285917.USD","GSKH","LU2417539215.USD","LU2237443465.HKD","GSK","BK4007","LU2237443978.SGD","BK4532","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642671094","title":"Nuvalent股价飙升 此前GSK宣布收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2642671094","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642671094?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:10","pubTimestamp":1781007000,"startTime":"0","endTime":"0","summary":"英国生物制药公司葛兰素史克宣布以106亿美元收购美国药企Nuvalent，后者股价随即飙升近39%。\n　　这项全现金交易对Nuvalent的估值约为每股124美元。Nuvalent目前有两款治疗某种肺癌的药物正在接受美国食品药品监督管理局的审评。\n　　葛兰素史克首席执行官卢克·米尔斯在新闻稿中表示，此次收购将为公司带来即时的新的销售增长机遇。这家药企在美国上市的股票周二盘前交易中下跌1%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniavmyr1715814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","GSK.UK","BK4532","NUVL","GSK","BK4588","BK4585","GSKH","BK4539","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642668054","title":"英国葛兰素史克斥资106亿美元收购美国药企Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2642668054","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642668054?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:28","pubTimestamp":1780997280,"startTime":"0","endTime":"0","summary":"英国制药集团葛兰素史克达成协议，以 106 亿美元收购美国药企 Nuvalent。本次收购正值全球生物医药并购热潮期。　　英国制药巨头葛兰素史克敲定收购美国药企 Nuvalent 的交易，交易总价 106 亿美元，核心目的是补强自身肺癌药物管线。　　葛兰素史克周二披露公告显示，本次交易为全现金收购，对 Nuvalent 的估值折合每股 124 美元，较该股前一交易日收盘价溢价 40%。　　英国《金融时报》周二早间率先曝出该并购消息，Nuvalent 方面暂未回应媒体置评请求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniauzkq6465243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","NUVL","BK4532","GSK","LU1829250122.USD","BK4139","BK4585","GSKH","GSK.UK","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642450645","title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2642450645","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642450645?lang=zh_cn&edition=full","pubTime":"2026-06-09 15:37","pubTimestamp":1780990654,"startTime":"0","endTime":"0","summary":"6月9日，$葛兰素史克$同意以106亿美元的价格收购肿瘤治疗药企Nuvalent。$葛兰素史克$周二发布声明称，将以每股124美元现金收购Nuvalent，较这家总部位于马萨诸塞州$剑桥$的公司周一收盘价溢价40%。此次收购标志着葛兰素史克癌症业务的重大扩张。Nuvalent的两款主要药物用于治疗携带特定基因突变的非小细胞肺癌患者。葛兰素史克表示，在获得监管部门批准后，对Nuvalent的收购预计将于第三季度完成。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451912.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NUVL","BK4139","BK4007","BK4532","BK4588","BK4585","GSKH","LU1829250122.USD","BK4539","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642567024","title":"最高溢价近43%!葛兰素史克(GSK.US)拟斥资90-100亿美元收购肿瘤药企Nuvalent(NUVL.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642567024","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642567024?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:18","pubTimestamp":1780975127,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克正就收购肿瘤治疗药企Nuvalent Inc.进行磋商，交易对价在90亿至100亿美元之间。本次交易将对总部位于马萨诸塞州剑桥市的Nuvalent给出高额溢价，这也将成为葛兰素史克史上规模最大的收购案之一。在退出肿瘤领域多年后，葛兰素史克近期才重新回归这一赛道。今年1月，葛兰素史克曾同意以22亿美元收购一家专注于炎症与免疫疾病治疗药物研发的美国生物科技公司Rapt Therapeutics，并在另一笔交易中获得了一款肺动脉高压药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4585","LU1829250122.USD","BK4532","GSK.UK","NUVL","GSK","BK4588","BK4539","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195440784","title":"最高溢价近43%！葛兰素史克拟斥资90-100亿美元收购肿瘤药企Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=1195440784","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195440784?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:14","pubTimestamp":1780967654,"startTime":"0","endTime":"0","summary":"6月9日，癌症生物技术公司Nuvalent夜盘涨超16%。据市场消息，葛兰素史克正就收购Nuvalent进行谈判，交易作价可能超过90亿美元，双方目标在本周内达成协议。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1451825.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["GSK","NUVL","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184442827","title":"异动解读｜葛兰素史克盘中上涨3.01%，乙肝功能性治愈新药三期数据积极且中国上市加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1184442827","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184442827?lang=zh_cn&edition=full","pubTime":"2026-06-05 03:53","pubTimestamp":1780602815,"startTime":"0","endTime":"0","summary":"6月5日，葛兰素史克盘中上涨3.01%，报51.22美元/股，成交额1.69亿美元。研究显示，该药6个月治疗后总体功能性治愈率达19%，低基线病毒活性人群治愈率达26%，中国亚组中HBsAg≤1000 IU/mL患者治愈率高达35%，安慰剂组为0%。此外，该药已在中国再次提交上市申请并获受理，纳入优先审评，GSK预计2027年上半年获中国药监局审批决定。杰富瑞预测其峰值年销售额达15亿美元，GSK内部预期更为乐观，有望突破27亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644648","title":"港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644648","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639644648?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:33","pubTimestamp":1780036423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨3.95%，报5港元，成交额4.28亿港元。消息面上，5月29日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的Bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。Bepirovirsen目前正在接受中国、美国、欧洲、日本监管机构的审评审批。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK4134","HK0000165453.HKD","01177","IE00BZ08YT58.USD","BK4532","LU1829250122.USD","IE00BZ08YS42.EUR","GSK","BK1191","GSKH","BK1515","BK4007","BK1589","III","BK4585","BK4588","GSK.UK","VXUS","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698093","title":"全球首项乙肝功能性治愈药物三期数据来了：这类患者，治愈率可达35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698093","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638698093?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:00","pubTimestamp":1779969642,"startTime":"0","endTime":"0","summary":"被视为有可能成为全球首款乙肝功能性治愈药物的贝普若韦生（Bepirovirsen），三期临床研究结果揭晓了。5月28日，葛兰素史克（GSK）在欧洲肝病学会（EASL）年会上公布了反义寡核苷酸（ASO）药物贝普若韦生两项全球三期临床试验（B-Well1和B-Well2）结果。结果也发表在全球顶刊《新英格兰医学杂志》上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605283752957045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605283752957045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4141","GSK.UK","GSKH","NA","BK4200","BK4007","ASO","BK4588","BK4532","LU1829250122.USD","BK4585","BK4561","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636356678?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ADC","GSK","BK4080","BK4231","GSKH","BK4585","BK4532","BK4007","LU1829250122.USD","BK4588","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634101862","title":"流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634101862","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634101862?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:05","pubTimestamp":1778594751,"startTime":"0","endTime":"0","summary":"金吾财讯 | 汉坦病毒疫情叠加药企药物研发/合作进展向好消息提振，美股流行病诊疗板块多股扬升，截至发稿，葛兰素史克  涨 1.93%，雅培  涨 1.60%，默沙东  涨 1.41%，阿斯利康  涨 1.18%，强生  涨 1.12%。达歌生物周二宣布与默沙东研发(中国)有限公司签署合作协议，共同推进抗肿瘤药物临床合作开发。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1121112475.USD","LU2236285917.USD","LU1551013425.SGD","LU0265550359.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU1201861249.SGD","LU0868494708.USD","LU2896262040.SGD","LU0466842654.USD","LU2237443895.HKD","LU0211331839.USD","LU2505996509.AUD","LU2471134879.HKD","BK4559","GSKH","LU2417539215.USD","LU0545562505.USD","LU0289739699.SGD","BK4592","IE00B1BXHZ80.USD","LU0477156953.USD","LU1221951129.SGD","IE0002270589.USD","LU1066051225.USD","SG9999015358.SGD","IE0000B7K699.USD","LU1145028129.USD","IE000SO60NU8.SGD","LU2430703251.USD","LU1430594728.SGD","LU1732800096.USD","LU2023250504.SGD","IE0001KFT4U8.USD","IE00B19Z3B42.SGD","LU2357627491.SGD","LU2023250330.USD","LU2213496289.HKD","LU2491050154.USD","IE000BZT7R73.USD","LU1691799644.USD","LU1244550577.SGD","SG9999001176.SGD","LU1989763427.SGD","LU0859254822.USD","LU1989763690.USD","LU2133065610.SGD","LU0266013472.USD","LU0265550946.USD","BK4504","LU0985320562.USD","IE00B2B36J28.USD","LU1674673691.USD","IE00B19Z3581.USD","LU1261432733.SGD","LU2461242641.AUD","LU0882574055.USD","LU0965509010.AUD","LU2487616109.SGD","IE00B4R5TH58.HKD","ABT","LU1228905540.USD","LU1066053197.SGD","LU1116320737.USD","SG9999014542.SGD","IE00BBT3K403.USD","LU0058720904.USD","LU0795875169.SGD","LU1221951046.USD","LU0234572021.USD","LU0942090050.USD","LU1066051498.USD","LU1066051811.HKD","SG9999013999.USD","IE0009355771.USD","LU0124676726.USD","LU2106854487.HKD","LU0689472784.USD","LU1732799900.SGD","LU0820561818.USD","LU2023250843.SGD","LU0345769128.USD","LU0234570918.USD","LU1989771016.USD","LU2237443622.USD","LU0820562030.AUD","BK4585","LU2129689431.USD","LU1778281490.HKD","LU2756315664.SGD","LU0122379950.USD","LU1023059063.AUD","LU2403377893.USD","LU0965508806.USD","IE00B42XCP33.USD","LU0426412945.USD","LU0861579265.USD","LU1934455277.USD","LU1037948541.HKD","JNJ","LU0130517989.USD","LU2505996681.GBP","LU1228905037.USD","BK4516","LU0238689110.USD","LU1035773651.USD","LU0345769631.USD","SG9999004303.SGD","LU1506573853.SGD","LU1974910355.USD","LU2211815571.USD","LU1674673428.USD","BK4082","LU2361044949.HKD","LU0426417589.USD","LU1917777945.USD","SG9999001440.SGD","LU2361044865.SGD","LU0070302665.USD","SG9999002232.USD","IE0034235303.USD","LU0208291251.USD","LU0210536198.USD","IE00BLSP4452.SGD","LU0203347892.USD","LU1894683348.USD","LU2347655156.SGD","LU1043141123.HKD","LU0006306889.USD","LU0964807845.USD","LU0640476718.USD","LU1267930813.SGD","SG9999015341.SGD","LU1989772840.SGD","LU2491049909.HKD","IE00BVYPNV92.GBP","LU2237443549.SGD","BK4533","LU0432979614.USD","LU2237957811.SGD","GSK.UK","LU1043141396.HKD","LU2471134952.CNY","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU0053666078.USD","LU1934455194.USD","IE00BFXG1179.USD","LU1983299246.USD","IE000M9KFDE8.USD","IE000MB6IJN5.SGD","LU0320765646.SGD","IE00BGHQF631.EUR","LU0203345920.USD","SGXZ41872573.SGD","LU0109394709.USD","LU1496350502.SGD","SG9999014575.USD","LU2602419157.SGD","IE00B7SZLL34.SGD","IE00BN8TJ469.HKD","AZN","BK4550","SG9999014567.USD","LU1057294990.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4581","IE00BVYPNW00.USD","LU1721429402.USD","BK4588","LU0787776722.HKD","LU1585245621.USD","LU0965509283.SGD","SG9999001176.USD","LU2112291526.USD","LU2360032135.SGD","LU2756315318.SGD","LU1032466523.USD","LU0792757196.USD","BK4566","LU2237443978.SGD","LU1721429741.USD","LU2237957902.USD","BK4568","IE00B3T34201.USD","LU1914381329.SGD","LU2125154935.USD","LU2456880835.USD","LU1571399168.USD","LU2430703178.SGD","LU1829250122.USD","LU0098860793.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU2237443465.HKD","LU0114720955.EUR","LU1718418525.SGD","LU0889566641.SGD","AZNH","IE000F7OJYX1.SGD","LU1894683264.USD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU0070217475.USD","LU2089984988.USD","SGXZ57979304.SGD","LU1069347547.HKD","LU0170899867.USD","LU1074936037.SGD","LU1929549753.HKD","IE00BKVL7J92.USD","LU1244550221.USD","LU2471134796.USD","LU1280957306.USD","IE00BSNM7G36.USD","LU1162221912.USD","LU1934455863.HKD","LU0980610538.SGD","LU1941712264.USD","LU1059921491.USD","SG9999014559.SGD","LU2592432038.USD","LU2324357040.USD","LU1699723380.USD","LU0912757837.SGD","LU2361045086.USD","LU2129689514.USD","LU1291159041.SGD","LU1629891620.HKD","LU2462157665.USD","LU2491050071.SGD","SG9999002224.SGD","LU0648001328.SGD","LU0689626769.HKD","LU1941712348.USD","SGXZ23171101.USD","GSK","LU0820561909.HKD","LU0345770308.USD","BK4532","LU1093756325.SGD","LU1116320901.HKD","LU0320765489.SGD","LU0795875086.SGD","LU1093756168.USD","LU1196500208.SGD","LU1935042991.SGD","LU0106261372.USD","LU2750360997.AUD","LU0965509101.SGD","IE000WAW04H5.SGD","LU2129689605.HKD","LU0868494617.USD","LU2237443382.USD","LU1551013342.USD","LU0683600562.USD","LU2430703095.HKD","LU0130102774.USD","LU2125154778.USD","LU0994945656.USD","LU1032955483.USD","LU1989772923.USD","LU0320765992.SGD","IE0002141913.USD","LU2471134523.USD","MRK","LU2750360641.GBP","LU0345770993.USD","LU0210528500.USD","BK4534","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634338289","title":"中国生物制药涨超4%：牵手GSK合作乙肝临床治愈明星产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2634338289","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634338289?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:58","pubTimestamp":1778500680,"startTime":"0","endTime":"0","summary":"全球首款有望最快实现乙肝功能性治愈的重磅药物被中国生物制药收入囊中！5月11日，中国生物制药（1177.HK）正式宣布，核心子公司正大天晴药业集团与知名跨国药企葛兰素史克（LSE/NYSE：GSK）达成独家战略合作，将加速一款名为bepirovirsen的药物在中国的上市进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733296932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733296932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","BK1589","GSKH","BK1191","BK1521","BK1515","BK4585","BK4588","IE00BZ08YT58.USD","01177","LU1829250122.USD","GSK.UK","IE00BZ08YS42.EUR","GSK","HK0000165453.HKD","IE00BZ08YR35.GBP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634405436","title":"正大天晴牵手GSK，瞄准乙肝百亿美元赛道商业化棋局","url":"https://stock-news.laohu8.com/highlight/detail?id=2634405436","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634405436?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:26","pubTimestamp":1778484360,"startTime":"0","endTime":"0","summary":"中国乙肝治疗药物市场正在迎来一个关键变量。5月11日，中国生物制药（1177.HK）公告，其核心子公司正大天晴与葛兰素史克（GSK）就反义寡核苷酸（ASO）药物Bepirovirsen达成独家战略合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733015888.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733015888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","BK4585","LU1829250122.USD","BK4588","GSK","GSK.UK","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634010474","title":"港股异动 | 中国生物制药(01177)午后涨超4% 正大天晴与葛兰素史克合作乙肝治愈重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2634010474","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634010474?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:35","pubTimestamp":1778477746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药午后涨超4%，截至发稿，涨4.05%，报5.65港元，成交额2.78亿港元。消息面上，中国生物制药午间公告，集团附属公司正大天晴与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1829250122.USD","IE00BZ08YS42.EUR","BK4588","VXUS","BK4532","01177","BK4585","IE00BZ08YR35.GBP","GSKH","BK1515","BK1589","GSK.UK","GSK","HK0000165453.HKD","IE00BZ08YT58.USD","BK4007","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634147972","title":"中国生物制药(01177)与葛兰素史克达成独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2634147972","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634147972?lang=zh_cn&edition=full","pubTime":"2026-05-11 12:26","pubTimestamp":1778473605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。通过持续深化与全球领先药企的战略合作，集团进一步巩固了作为MNC在中国首选合作伙伴的行业领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1521","BK4532","IE00BZ08YR35.GBP","GSK.UK","BK4007","LU1829250122.USD","01177","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","BK4585","BK1191","GSK","BK1515","GSKH","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633512166","title":"时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2633512166","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633512166?lang=zh_cn&edition=full","pubTime":"2026-05-07 07:00","pubTimestamp":1778108408,"startTime":"0","endTime":"0","summary":"丨2026年5月7日星期四丨NO.1时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作时安生物宣布，与葛兰素史克（GSK）就SA030达成一项中国市场以外的全球独家许可协议。葛兰素史克将支付首付款，以及未来基于成功达成的开发、注册与商业化里程碑付款，总额最高达10.05亿美元；同时将按中国以外的全球产品净销售额支付分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073729101163.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073729101163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","09939","GSK.UK","603168","BK1574","BK4588","BK0239","BK4585","BK4532","GSK","BK4007","BK1515","BK1161","159938","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633905567","title":"花旗：将葛兰素史克目标价下调至2100便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2633905567","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633905567?lang=zh_cn&edition=full","pubTime":"2026-05-06 13:37","pubTimestamp":1778045821,"startTime":"0","endTime":"0","summary":"花旗集团将葛兰素史克目标股价从2250便士下调至2100便士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260506/32202409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0361},{"period":"1month","weight":0.0178},{"period":"3month","weight":-0.0249},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.3619},{"period":"ytd","weight":0.0706}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010267},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}